Gefitinib

Evidence Level: L5

Predicted Indications: 9

Gefitinib

Pharmacist Assessment Report

Gefitinib: From Non-Small Cell Lung Cancer to Fibromatosis, Gingival

One-Sentence Summary

Gefitinib is an oral EGFR tyrosine kinase inhibitor, originally used to treat non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for gingival fibromatosis, but no clinical trials and no publications were found for this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Non-small cell lung cancer (lung cancer). The ARTG entry in the data compiled for this report has no approved indication text.
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	0.9989
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Based on known information, gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Its efficacy in EGFR-mutant NSCLC is well established.

Gingival fibromatosis is a fibroproliferative condition of the gums. A speculative link is EGFR/ErbB signalling in fibroblast proliferation. However, nothing in the compiled data supports this link, and the similarity between the original and predicted indications has not been assessed. The high score most likely reflects the model’s network patterns rather than a validated biological rationale.

Other top-ranked predictions were reviewed too. Most are also prediction-only (L5). The ones with literature are not gefitinib-specific:

Lung hilum carcinoma and pulmonary sulcus neoplasm are essentially lung cancers, so the existing EGFR-TKI rationale could apply to EGFR-mutant cases. The evidence is limited to case reports and general reviews, so these are best treated as research questions rather than new indications.
Lung germ cell tumour has one linked trial, which studied head and neck cancer and NSCLC rather than germ cell tumours.

Clinical Trial Evidence

Currently no related clinical trials registered for gingival fibromatosis.

Literature Evidence

Currently no related literature available for gingival fibromatosis.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 11264W	Cipla Gefitinib	Tablet 250 mg	Not stated in the compiled data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (EGFR tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Liver function and respiratory symptoms are of particular interest (see Safety Considerations). Please refer to the PI for the full monitoring schedule.
Handling Protection	Please refer to the PI and local cytotoxic or hazardous drug handling policies

Safety Considerations

Knowledge-graph contraindication signals (from drug-disease relationships, not label text): liver disease, gallbladder disease, interstitial lung disease, pulmonary fibrosis and post-inflammatory pulmonary fibrosis. Literature retrieved for other predictions also describes gefitinib-associated pneumonitis and interstitial lung disease, including a fatal case, QT prolongation (preclinical), and cutaneous toxicity (acneiform eruption, paronychia, xerosis).
Drug interactions: 100 interactions were identified, and the main ones listed are Moderate or Unknown severity.
- Acid-suppressing agents (H2 blockers and PPIs): famotidine, ranitidine, cimetidine, nizatidine, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole.
- Other moderate-level interactions: clarithromycin, aprepitant, dexamethasone, naltrexone, miconazole, clotrimazole, troglitazone.
- Unknown-level interactions: calcitriol, glimepiride.

Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label text was not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for gingival fibromatosis is supported only by a model score, with no clinical trials, no literature and no established mechanistic link. A skin and mucosal toxicity profile for gefitinib is also a potential concern in fibroproliferative or epithelial conditions.

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a documented rationale for EGFR/ErbB involvement in gingival fibroblast proliferation
Preclinical studies (for example fibroblast models) and a literature search specific to gingival fibromatosis
The TGA Product Information, including warnings, contraindications and the approved indication text, to enable safety screening
Assessment of route and dosing suitability, since only an oral 250 mg tablet is registered
Separately, consider whether the lung hilum carcinoma and pulmonary sulcus neoplasm predictions merit a research question, since they fall within the existing lung cancer setting
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.